Abstract:Normal vasculature is quiescent in healthy adults with each endothelial cell dividing once every 10 years. But, angiogenesis is crucial for the growth and metastasis of breast cancer, and has been targeted for developing therapeutics. The current treatments are effective in only a small percentage of the total patient population. In addition, they are expensive, and accompanied by a host of side effects detrimental to patient9s quality of life. Our laboratory has recently established that tunicamycin (an antibiotic and a glucosamine-containing pyrimidine nucleoside) interferes with the dynamic process of asparagine-linked protein glycosylation inhibiting angiogenesis in vitro and in vivo Matrigel ™ implants. It causes cell cycle arrest in G1 and induces endoplasmic reticulum (ER) stress-mediated unfolded protein response (upr), and apoptosis by down regulated expression of Bcl-2 and cyclin D1, and upregulated expression of GRP-78/Bip and caspases3, 9 and 12. High expression of ATF6 and PERK in capillary endothelial cells indicates transcriptional and translational attenuation. Irreversibility of cellular proliferation by either IGF-1 or VEGF or inhibition of cell growth by clonogenic assay supports that tunicamycin can stand tumor microenvironment. There is down-regulation of phosphotyrosine kinase activity as well as the phosphoVEGFR1 and VEGFR2 levels. Most importantly, tunicamycin reduces the progression of a double negative (ER − /PR − /EGFR + ) grade III breast adenocarcinoma and a triple negative (ER − /PR − /EGFR − ) breast tumor xenograft in nude mice. Histopathology indicates reduced microvascular density and low tumor mitotic index along with reduced K-67 and VEGF expression. A significant reduction of N-glycan expression on the vessel wall correlates with the vessels size, and a high expression of GRP-78/Bip in CD144 positive vessels supports vessel death due to ER stress-mediated upr. WGA staining of tumor epithelia indicates loss of structural integrity with a high GRP-78/Bip expression, and has raised a question if induction of ER stress in tumor epithelia is an indirect effect of nutrient deprivation due to reduced blood flow in the absence of angiogenesis or does tunicamycin directly induce ER stress in the tumor cells. To test this hypothesis we have used a triple negative MDA-MB-231 human breast cancer cell line and cultured them with tunicamycin in a custom made media. Our results show that tunicamycin inhibits cell proliferation in a dose- and time-dependent manner as well as the colony formation. Expression of cyclin D1, wild type p53, phopspho p53(ser 392), Bcl-2 and caspase-3 supports cell cycle arrest followed by induction of apoptosis. High expression of GRP-78 and PERK/phosphoPERK concludes that tunicamycin can induce ER stress-mediated upr in MDA-MB-231 breast cancer cells. Supported in part by grants from Susan G. Komen for the Cure (BCTR06582) and NIH/NCRR/RCMI G12-RR03035 (KB) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2313. doi:1538-7445.AM2012-2313

Tunicamycin interferes with WNT signaling and inhibits angiogenesis

Inhibition of N-Linked Glycosylation by Tunicamycin Enhances Sensitivity to Cisplatin in Human Head-And-Neck Carcinoma Cells

Er Stress-Mediated Unfolded Protein Response Inhibits Angiogenesis And Breast Tumor Growth

Abstract 2095: Tunicamycin inhibits triple negative breast cancer progression

Tunicamycin-induced endoplasmic reticulum stress reduces in vitro subpopulation and invasion of CD44+/CD24- phenotype breast cancer stem cells

<Emphasis Type="Italic">N</Emphasis>-Acetylglucosaminyl 1-Phosphate Transferase: An Excellent Target for Developing New Generation Breast Cancer Therapeutic

Tunicamycin Induces ER Stress and Inhibits Tumorigenesis of Head and Neck Cancer Cells by Inhibiting N-glycosylation

Tunicamycin Inhibits Cell Proliferation and Migration in Hepatocellular Carcinoma Through Suppression of CD44s and the ERK1/2 Pathway

ARTEMIN Synergizes with TWIST1 to Promote Metastasis and Poor Survival Outcome in Patients with ER Negative Mammary Carcinoma.

Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers

Artemin Promotes De Novo Angiogenesis in Er Negative Mammary Carcinoma Through Activation of Twist1-Vegf-A Signalling

Artemin Stimulates Radio- and Chemo-Resistance by Promoting TWIST1-BCL-2-dependent Cancer Stem Cell-Like Behavior in Mammary Carcinoma Cells.

Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer

Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation

Tunicamycin-induced ER Stress in Breast Cancer Cells Neither Expresses GRP78 on the Surface nor Secretes It into the Media

Upregulated Expression of Grp78 Supports Er Stress-Induced Apoptosis in Tunicamycin Treated Triple Negative Breast Tumor

Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway

Tubulin Carboxypeptidase Activity Promotes Focal Gelatin Degradation in Breast Tumor Cells and Induces Apoptosis in Breast Epithelial Cells That Is Overcome by Oncogenic Signaling

Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress

Unraveling the Action Mechanism of Tubeimoside-1 against Tumor Microvessels via Network Pharmacology and Experimental Validation

Tunicamycin Potentiates Cisplatin Anticancer Efficacy Through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma.